Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026 Cision · Nov 3, 2026
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Globe Newswire · Nov 2, 2026
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease Globe Newswire · Nov 2, 2026
Kraig Biocraft Laboratories Takes Spider Silk Optimization Beyond Genetics with New Dietary Additive Program Globe Newswire · Nov 2, 2026
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 Cision · Nov 2, 2026
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE Globe Newswire · Oct 31, 2026
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cision · Oct 31, 2026
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) Cision · Oct 31, 2026
